HCM
BIO icon

Highbridge Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Highbridge Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$200K – 1639
2017
Q3 		$200K Buy
+1,000
New +$225K ﹤0.01% 1422

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Highbridge Capital Management's BIO Position: Q3 2017 in Review

Highbridge Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2017, closing a stake of 1,932 shares — an estimated $435K sold.

Highbridge Capital Management first reported a position in BIO in Q2 2013 and held it in 6 quarters. The position peaked at $5.8M in Q3 2013. 271 funds tracked by Wall St. Rank hold BIO as of Q3 2017.

  • Highbridge Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 1,932 Bio-Rad Laboratories Class A shares in Q3 2017, an estimated $435K.
  • Highbridge Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 6 quarters.
  • Highbridge Capital Management's Bio-Rad Laboratories Class A position peaked at $5.8M in Q3 2013.
  • 271 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.